NEXTWAVE PHARMACEUTICALS Trademark

Trademark Overview

On Wednesday, August 24, 2011, a trademark application was filed for NEXTWAVE PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the NEXTWAVE PHARMACEUTICALS trademark a serial number of 85406355. The federal status of this trademark filing is REGISTERED AND RENEWED as of Monday, March 18, 2024. This trademark is owned by NextWave Pharmaceuticals Incorporated. The NEXTWAVE PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment [ of hypertension; pharmaceuticals ] for the treatment of attention deficit hyperactivity disorder (ADHD); [ pharmaceuticals for the treatment of cardiovascular diseases; ] pharmaceuticals for the treatment of central nervous system diseases
nextwave pharmaceuticals

General Information

Serial Number85406355
Word MarkNEXTWAVE PHARMACEUTICALS
Filing DateWednesday, August 24, 2011
Status800 - REGISTERED AND RENEWED
Status DateMonday, March 18, 2024
Registration Number4425993
Registration DateTuesday, October 29, 2013
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 7, 2012

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment [ of hypertension; pharmaceuticals ] for the treatment of attention deficit hyperactivity disorder (ADHD); [ pharmaceuticals for the treatment of cardiovascular diseases; ] pharmaceuticals for the treatment of central nervous system diseases
Disclaimer with Predetermined Text"PHARMACEUTICALS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, August 30, 2011
Primary Code005
First Use Anywhere DateThursday, January 31, 2013
First Use In Commerce DateThursday, January 31, 2013

Trademark Owner History

Party NameNextWave Pharmaceuticals Incorporated
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMonmouth Junction, NJ 08852
Party NameNextWave Pharmaceuticals Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCupertino, CA 95014
Party NameNextWave Pharmaceuticals Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCupertino, CA 95014

Trademark Events

Event DateEvent Description
Monday, March 18, 2024NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Monday, March 18, 2024REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Monday, March 18, 2024REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Monday, March 18, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Friday, October 13, 2023TEAS SECTION 8 & 9 RECEIVED
Saturday, October 29, 2022COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Sunday, December 1, 2019NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Sunday, December 1, 2019REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Sunday, December 1, 2019CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, October 28, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, October 28, 2019TEAS SECTION 8 & 15 RECEIVED
Tuesday, February 5, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 5, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, October 29, 2018COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, October 3, 2018ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, October 29, 2013REGISTERED-PRINCIPAL REGISTER
Thursday, September 26, 2013NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, September 25, 2013LAW OFFICE REGISTRATION REVIEW COMPLETED
Tuesday, September 24, 2013ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Monday, September 23, 2013SOU TEAS EXTENSION RECEIVED
Monday, September 23, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 23, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 23, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 3, 2013NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 3, 2013NON-FINAL ACTION E-MAILED
Wednesday, April 3, 2013SU - NON-FINAL ACTION - WRITTEN
Thursday, March 21, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 20, 2013STATEMENT OF USE PROCESSING COMPLETE
Monday, March 18, 2013USE AMENDMENT FILED
Wednesday, March 20, 2013SOU EXTENSION 2 GRANTED
Monday, March 18, 2013SOU EXTENSION 2 FILED
Monday, March 18, 2013SOU TEAS EXTENSION RECEIVED
Monday, March 18, 2013TEAS STATEMENT OF USE RECEIVED
Thursday, December 13, 2012ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, December 13, 2012TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, October 6, 2012NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 5, 2012SOU EXTENSION 1 GRANTED
Wednesday, October 3, 2012SOU EXTENSION 1 FILED
Friday, October 5, 2012CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 3, 2012SOU TEAS EXTENSION RECEIVED
Tuesday, April 3, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 7, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 7, 2012PUBLISHED FOR OPPOSITION
Wednesday, January 18, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, January 5, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, January 5, 2012ASSIGNED TO LIE
Wednesday, December 14, 2011APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 14, 2011EXAMINER'S AMENDMENT ENTERED
Wednesday, December 14, 2011NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, December 14, 2011EXAMINERS AMENDMENT E-MAILED
Wednesday, December 14, 2011EXAMINERS AMENDMENT -WRITTEN
Tuesday, December 13, 2011ASSIGNED TO EXAMINER
Tuesday, August 30, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 27, 2011NEW APPLICATION ENTERED

Related Keywords

pharmaceuticals nextwave treatment diseases central nervous system cardiovascular disorder hypertension attention